Literature DB >> 20135358

Side populations of glioblastoma cells are less sensitive to HSV-TK/GCV suicide gene therapy system than the non-side population.

Weiwei Hu1, Weiguo Liu.   

Abstract

Side populations of glioblastoma cells are resistant to chemotherapy basically due to ABCG2-mediated efflux of small-molecule drugs. The herpes simplex virus thymidine kinase/ganciclovir suicide gene therapy system is one of the best-characterized strategies for malignant tumors including glioblastoma. Since this system involves a small-molecule drug ganciclovir, we wonder if glioblastoma side population cells are able to "pump out" ganciclovir and thus resistant to this suicide gene therapy. By 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay, we found that side populations are more resistant to this system than non-side populations. By flow cytometry and competition assay, we found that ganciclovir is a substrate for ABCG2.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20135358     DOI: 10.1007/s11626-010-9274-6

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.416


  21 in total

1.  Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma.

Authors:  N G Rainov; C Fels; J W Droege; C Schäfer; C M Kramm; T C Chou
Journal:  Cancer Gene Ther       Date:  2001-09       Impact factor: 5.987

2.  Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme.

Authors:  N G Rainov; C M Kramm; U Banning; D Riemann; H J Holzhausen; V Heidecke; K J Burger; W Burkert; D Körholz
Journal:  Gene Ther       Date:  2000-11       Impact factor: 5.250

3.  Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy.

Authors:  F L Moolten
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

4.  Combination gene therapy for glioblastoma involving herpes simplex virus vector-mediated codelivery of mutant IkappaBalpha and HSV thymidine kinase.

Authors:  Shusuke Moriuchi; Joseph C Glorioso; Motohiko Maruno; Shuichi Izumoto; Darren Wolfe; Shaohua Huang; Justus B Cohen; Toshiki Yoshimine
Journal:  Cancer Gene Ther       Date:  2005-05       Impact factor: 5.987

5.  Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.

Authors:  Gaspar J Kitange; Brett L Carlson; Mark A Schroeder; Patrick T Grogan; Jeff D Lamont; Paul A Decker; Wenting Wu; C David James; Jann N Sarkaria
Journal:  Neuro Oncol       Date:  2008-10-24       Impact factor: 12.300

6.  Long-term glioblastoma multiforme survivors: a population-based study.

Authors:  J N Scott; N B Rewcastle; P M Brasher; D Fulton; N A Hagen; J A MacKinnon; G Sutherland; J G Cairncross; P Forsyth
Journal:  Can J Neurol Sci       Date:  1998-08       Impact factor: 2.104

Review 7.  Cancer stem cells in nervous system tumors.

Authors:  Sheila K Singh; Ian D Clarke; Takuichiro Hide; Peter B Dirks
Journal:  Oncogene       Date:  2004-09-20       Impact factor: 9.867

8.  PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.

Authors:  Anne-Marie Bleau; Dolores Hambardzumyan; Tatsuya Ozawa; Elena I Fomchenko; Jason T Huse; Cameron W Brennan; Eric C Holland
Journal:  Cell Stem Cell       Date:  2009-03-06       Impact factor: 24.633

9.  In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors.

Authors:  K W Culver; Z Ram; S Wallbridge; H Ishii; E H Oldfield; R M Blaese
Journal:  Science       Date:  1992-06-12       Impact factor: 47.728

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  7 in total

1.  Enzyme/Prodrug Systems for Cancer Gene Therapy.

Authors:  Obeid M Malekshah; Xuguang Chen; Alireza Nomani; Siddik Sarkar; Arash Hatefi
Journal:  Curr Pharmacol Rep       Date:  2016-10-19

Review 2.  Gene-directed enzyme prodrug therapy.

Authors:  Jin Zhang; Vijay Kale; Mingnan Chen
Journal:  AAPS J       Date:  2014-10-23       Impact factor: 4.009

3.  Human ABCG2: structure, function, and its role in multidrug resistance.

Authors:  Wei Mo; Jian-Ting Zhang
Journal:  Int J Biochem Mol Biol       Date:  2011-03-30

Review 4.  The art of gene therapy for glioma: a review of the challenging road to the bedside.

Authors:  Alex Tobias; Atique Ahmed; Kyung-Sub Moon; Maciej S Lesniak
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-09-19       Impact factor: 10.154

5.  Frontiers in Suicide Gene Therapy of Cancer.

Authors:  Marek Malecki
Journal:  J Genet Syndr Gene Ther       Date:  2012-10-22

6.  The Oncogenic Action of NRF2 Depends on De-glycation by Fructosamine-3-Kinase.

Authors:  Viraj R Sanghvi; Josef Leibold; Marco Mina; Prathibha Mohan; Marjan Berishaj; Zhuoning Li; Matthew M Miele; Nathalie Lailler; Chunying Zhao; Elisa de Stanchina; Agnes Viale; Leila Akkari; Scott W Lowe; Giovanni Ciriello; Ronald C Hendrickson; Hans-Guido Wendel
Journal:  Cell       Date:  2019-08-08       Impact factor: 66.850

7.  Suicide Gene Therapy Mediated with Exosomes Produced by Mesenchymal Stem/Stromal Cells Stably Transduced with HSV Thymidine Kinase.

Authors:  Andrea Pastorakova; Jana Jakubechova; Ursula Altanerova; Cestmir Altaner
Journal:  Cancers (Basel)       Date:  2020-04-28       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.